10 completed, 3 active not recruiting, 3 recruiting. 8 Phase 4, 5 Phase 2, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 5, Recruiting 2, Active not recruiting 1 |
| Phase 2 | 5 | Completed 3, Active not recruiting 2 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Canadian Immunization Research Network: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine Haemophilus influenzae serotype a vaccine candidate, Saline (as a placebo) - Haemophilus Influenzae, Haemophilus Influenzae Type a | Phase 2 | Active not recruiting | InventVacc Biologicals Inc. | 47 | 2026-04-29 | 2026-08-03 |
| Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies Co-payment Model - Step 1, Co-payment Model - Step 2, Co-payment Model - Step 3 - Preventable Disease, Vaccine | Not applicable | Recruiting | Canadian Immunization Research Network | 600 | 2025-10-23 | 2026-03-19 |
| Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy Tdap Vaccine Administration, RSV Vaccine, Saline (as a placebo) - RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination | Phase 4 | Recruiting | Canadian Immunization Research Network | 60 | 2025-10-16 | 2026-10-22 |
| Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart H5N1 vaccine (Arepanrix), Saline (as a placebo) - H5N1 Influenza, H5N1 Virus | Phase 4 | Active not recruiting | Canadian Immunization Research Network | 312 | 2025-10-14 | 2026-01-16 |
| Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students HPV nonavalent vaccine (Gardasil-9) - HPV Vaccine | Phase 4 | Recruiting | Canadian Immunization Research Network | 300 | 2025-09-23 | 2025-09-29 |
| Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity mRNA-1273 SARS-CoV-2 vaccine, BNT162b2, ChAdOx1-S [recombinant] - COVID-19 | Phase 2 | Active not recruiting | Canadian Immunization Research Network | 669 | 2021-05-20 | 2025-03-18 |
| CT18 Infant Influenza Priming Study in Vaccine Naive Infants aTIV Primer, QIV Primer, aTIV Booster - Influenza | Phase 2 | Completed | Canadian Immunization Research Network | 159 | 2018-11-01 | 2023-03-28 |
| Adolescent MenACWY Booster Study MenACWY-CRM, MenACWY-DT, MenACWY-TT - Meningococcal Disease, Invasive | Phase 4 | Completed | Canadian Immunization Research Network | 244 | 2018-09-20 | 2022-03-11 |
| CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study PCV13 - Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection | Phase 2 / Phase 3 | Completed | University of British Columbia | 248 | 2018-08-23 | 2024-03-04 |
| Public Health Messages to Address Vaccine Hesitancy Parent source, Doctor source, Deliberative content - Vaccine Hesitancy | Not applicable | Completed | University of Manitoba | 883 | 2018-07-09 | 2019-10-10 |
| African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine, Saline - Ebola | Phase 2 | Completed | Canadian Immunization Research Network | 251 | 2017-08-01 | 2026-01-12 |
| Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction Meningococcal B, High-Dose TIV, Tdap (tetanus-diphtheria-acellular pertussis) - Healthy | Phase 4 | Completed | Canadian Immunization Research Network | 2404 | 2017-02-15 | 2024-12-16 |
| Vaccinating Children After Chemotherapy Prevnar®13, Pneumovax® 23, Pediacel® - Acute Lymphoblastic Leukemia | Phase 4 | Completed | Canadian Immunization Research Network | 156 | 2015-11-16 | 2022-06-24 |
| Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults Bexsero®, Havrix® - Meningococcal Serogroup B | Phase 4 | Completed | Canadian Immunization Research Network | 120 | 2015-09-01 | 2019-01-31 |
| Hepatitis B Booster Study in Adolescence EngerixB, GlaxoSmithKline Vaccines - Hepatitis B | Phase 4 | Completed | University of British Columbia | 359 | 2014-09-01 | 2019-03-21 |
| Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization 4CMenb, diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB, conjugated pneumococcal vaccine - Meningococcal Infections | Completed | CHU de Quebec-Universite Laval | 4535 | 2008-08-01 | 2019-08-07 |
Meningococcal Infections (2) · COVID-19 (1) · Diphtheria (1) · Haemophilus Infections (1) · Hemorrhagic Fever, Ebola (1) · Hepatitis B (1) · Influenza in Birds (1) · Influenza, Human (1) · Pneumococcal Infections (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Vaccination Hesitancy (1) · Vaccine-Preventable Diseases (1)
Sodium Chloride (4) · 4CMenB vaccine (3) · Saline Solution (3) · Hepatitis A Vaccines (2) · 13-valent pneumococcal vaccine (1) · 2019-nCoV Vaccine mRNA-1273 (1) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Appointments and Schedules (1) · BNT162 Vaccine (1) · Boostrix (1) · ChAdOx1 nCoV-19 (1) · Ebola Vaccines (1) · Hepatitis B Vaccines (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Herpes Zoster Vaccine (1)
Canada (15)
Joanne M Langley, MD (2) · Bahaa Abu-Raya, M.D., PhD (1) · Cecile Tremblay, MD (1) · Chantal Sauvageau, MD (1) · David Scheifele, MD (1) · Emily Black, PharmD (1) · Gaston De Serres, MD, PhD (1) · Joanne Langley (1) · Joanne M Langley (1) · Joanne M Langley, MD, MSc, FRCPC (1) · Karina Top, MD, MS (1) · Manish Sadarangani, BM BCh DPhil (1) · Manish Sadarangani, MD (1) · Michelle Driedger, PhD (1) · Scott A Halperin, MD (1)
PMID 28134742, PMID 31110098, PMID 31270173, PMID 32067048, PMID 42567171